The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

(2018) Junko Tanizaki et al.   Journal of Thoracic Oncology

CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma

(2018) Hiromichi Shirasu et al.   TUMOR BIOLOGY

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

(2017) Stefan Diem et al.   LUNG CANCER

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

(2017) Vivian Barak et al.   Cancer Biomarkers

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

(2017) Stefan Holdenrieder et al.   Cancer Biomarkers

Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer

(2016) Rafael Molina et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis

(2016) Brian J. Anderson et al.   JOURNAL OF CRITICAL CARE

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis

(2016) Hossein Borghaei et al.   Journal of Thoracic Oncology

Biomarkers along the continuum of care in lung cancer

(2016) Stefan Holdenrieder   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer

(2016) Shirish Gadgeel et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients

(2016) Zuxun (Peter) Cai   OncoTargets and Therapy

Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology

(2015) Meagan S. Barbee et al.   ANNALS OF PHARMACOTHERAPY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream

(2015) Helga Sertić Milić et al.   WIENER KLINISCHE WOCHENSCHRIFT

Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer

(2015) Zhi-Hui Zhang et al.   Cancer Medicine

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer

(2014) Dong Soo Lee et al.   Journal of Cancer

Role of immunotherapy in the treatment of advanced non-small-cell lung cancer

(2013) Erika Rijavec et al.   Future Oncology

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

(2011) Juan Wang et al.   TUMOR BIOLOGY

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER